Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Injectafer is a prescription intravenous iron replacement product containing ferric carboxymaltose. It treats iron deficiency anemia in adults and children age 1 and older who cannot tolerate oral iron or have an unsatisfactory response to it, and in adults with non-dialysis dependent chronic kidney disease. It also treats iron deficiency in adults with New York Heart Association class II or III heart failure to improve exercise capacity.
read more about injectafer ...Ferric carboxymaltose supplies iron that enters normal iron transport and storage pathways after intravenous administration. The iron becomes available for incorporation into hemoglobin and replenishment of body iron stores.
Injectafer is used for iron deficiency anemia in adults and pediatric patients age 1 and older when oral iron is not tolerated or gives an unsatisfactory response. Adults with non-dialysis dependent chronic kidney disease are also included. A separate indication covers iron deficiency in adults with class II or III heart failure to improve exercise capacity.
Patients weighing 50 kg or more receive 750 mg intravenously in two doses separated by at least seven days for a total of 1500 mg per course. Adults weighing 50 kg or more can instead receive 15 mg per kg up to 1000 mg as one dose per course. Patients weighing less than 50 kg receive 15 mg per kg in two doses separated by at least seven days.
Injectafer carries a boxed warning for severe and prolonged hypophosphatemia, which has been associated with hospitalization, osteomalacia, and fractures. Other serious concerns include hypersensitivity reactions and increased blood pressure. Serum phosphate is checked before selected repeat courses, and pre-existing hypophosphatemia is corrected before treatment.
Injectafer treats selected cases of iron deficiency anemia and iron deficiency in adults with class II or III heart failure.
A common course is 750 mg intravenously twice, with the doses separated by at least seven days.
Yes. Severe and prolonged hypophosphatemia can occur and is the subject of the current boxed warning.
Serum phosphate is checked before a repeat course in patients at risk for low phosphate and in patients receiving another course within three months.
FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-boxed-warning-labeling-ferric-carboxymaltose-injection-injectafer-describe-risk-low. Date Accessed October 5, 2026.
Ferric Carboxymaltose Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a614037.html. Date Accessed October 5, 2026.
INJECTAFER (Ferric Carboxymaltose) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de. Date Accessed October 5, 2026.
INJECTAFER Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203565s030lbl.pdf. Date Accessed October 5, 2026.
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/40159390/. Date Accessed October 5, 2026.